Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Epistem Announces Executive Board Appointments

Published: Monday, January 27, 2014
Last Updated: Monday, January 27, 2014
Bookmark and Share
Dr Allan Brown joins the Board as Chief Operating Officer of the Diagnostics division of the Company, with effect from 1st February, 2014.

Epistem also announce the appointment of Dr Peter Foster as Technical Director of Epistem’s Diagnostics division.

Allan Brown, aged 52, has spent his career in the Life Sciences/diagnostics industry. During a seventeen year period with Tepnel Life Sciences plc (“Tepnel”) latterly as Divisional Managing Director, Allan’s technical management roles covered product development through to commercial product launch and his commercial management roles covered sales and business development and M&A.   Allan left Tepnel in 2010 following its recommended US$132m cash offer by Gen-Probe Inc. in 2009.  At the time of the offer by Gen-Probe Inc. Tepnel employed over 200 employees and had operations in the UK, US, Belgium and France.   After leaving Gen-Probe Allan joined the leading Sample & Assay Technologies company, QIAGEN N.V., in Manchester and managed the final development and launch of the company’s first US FDA approved products, helping secure the site as QIAGEN’s Global Centre of Excellence for molecular diagnostic product development.

Peter Foster, aged 63, has also spent his career in medical diagnostics as a scientist and joins Epistem to oversee development of a portfolio of new molecular diagnostic tests for Genedrive®, Epistem’s handheld molecular diagnostic device. Peter was Technical Director at Shield Diagnostics which merged to become Axis-Shield PLC. Peter subsequently became CEO at Euro-Diagnostics in 2001 where he successfully developed a portfolio of new medical diagnostic products, including a new and now widely-used biomarker to diagnose rheumatoid arthritis, with end user sales of c.$50M pa. From 2007 to 2013, Peter worked in New Zealand both as the CEO of Symansis (until 2012) which developed reagents for use in cancer research and also as a non-executive director of Pacific Edge Limited which developed a test for bladder cancer. Latterly, Peter was National Manager with New Zealand’s Ministry of Business, Innovation and Employment overseeing science investments.

Matthew Walls, Chief Executive of Epistem, welcoming these appointments said “As Epistem gears up to exploit the many valuable opportunities ahead for Genedrive®, Allan Brown brings a wealth of diagnostics management experience to Epistem with a deep understanding of commercial and regulatory processes. Peter Foster’s heritage and experience as a scientist in medical diagnostics will greatly help Epistem rapidly develop our portfolio of products which will follow on from the launch of our first TB assay, scheduled for later this year.”

David Evans, non-executive Chairman of Epistem, said “The appointment of Allan Brown will extend the balance of our Board’s experience, to take account of the increasing influence of diagnostics within the Epistem portfolio of activities and, on behalf of shareholders, I extend a warm welcome to him. Further, having worked with Peter Foster at Shield Diagnostics, some time ago now, it is a great pleasure to welcome Peter to the diagnostics technical development team which he will be leading. I wish both Allan and Peter every success”

Save as disclosed herein, there are no additional disclosures to be made in accordance with paragraph (g) of Schedule 2 of the AIM Rules in relation to Allan Brown. 


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Epistem and CRT Announce Agreement
Agreement for the use of patient derived leukemic Primagraft samples.
Friday, May 01, 2015
UK-Norwegian Collaboration Aims to Develop a New Living Skin Equivalent Model
New in vitro human living skin equivalent model for testing inflammatory responses.
Tuesday, May 21, 2013
Epistem Announces Partnership with The University of Manchester
Partnership will allow Epistem to expand its wound healing models range.
Monday, November 14, 2011
Epistem Presents its new Ex Vivo Plucked Hair Biomarker Assay at EORTC-NCI-AACR Symposium
New method for maintaining plucked human hairs ex vivo, and treating with therapeutic agents to obtain information on the cellular response to drug treatment.
Friday, November 19, 2010
EpiStem Awarded Further Long Term Funding for NIH Biodefence Programme
The Company has been reappointed for up to five years to provide preclinical testing services as a subcontractor.
Wednesday, November 10, 2010
Epistem’s Biomarker Division Gains GCLP Accreditation
Division conducts gene expression analysis to support clinical drug development programs within pharmaceutical and biotechnology organizations.
Tuesday, June 08, 2010
Epistem’s Biomarker Focus in the US
Epistem Inc to maximize the awareness of Epistem Plc’s technology offering as well as support the commercialization of the GenetRx™ biomarker platform.
Friday, October 30, 2009
Epistem Presents Further Data Supporting its Plucked Hair Biomarker Technology
Data on the effects of Gemcitabine on epithelial tissue released at the Institute of Cancer Research Centenary Conference.
Thursday, June 11, 2009
Scientific News
The Mending Tissue - Cellular Instructions for Tissue Repair
NUS-led collaborative study identifies universal mechanism that explains how tissue shape regulates physiological processes such as wound healing and embryo development.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
iPS Cells Discover Drug Target for Muscle Disease
Researchers have designed a model that reprograms fibroblasts to the early stages of their differentiation into intact muscle cells in a step towards a therapeutic for Duchenne muscular dystrophy.
Engineered Hot Fat Implants Reduce Weight Gain
Scientists at UC Berkeley have developed a novel way to engineer the growth and expansion of energy-burning “good” fat, and then found that this fat helped reduce weight gain and lower blood glucose levels in mice.
Transplanted Stem Cells Can Benefit Retinal Disease Sufferers
Tests on animal models show that MSCs secrete growth factors that suppress causes of diabetic retinopathy and macular degeneration.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Team Finds Early Inflammatory Response Paralyzes T Cells
Findings could have enormous implications for immunotherapy, autoimmune disorders, transplants and other aspects of immunity.
Early Detection of Lung Cancer
The University of Manchester has signed a collaboration agreement with Abcodia to perform proteomics studies on a cohort of non-small cell lung cancer cases from the UKCTOCS biobank, with the aim of discovering new blood-based biomarkers for earlier detection of the disease.
Researchers Identify Drug Candidate for Skin, Hair Regeneration
Formerly undiscovered role of protein may lead to the development of new medications that stimulate hair and skin regeneration in trauma or burn victims.
Basis for New Treatment Options for a Fatal Leukemia in Children Revealed
Detailed molecular analyses allow new insights into the function of tumour cells and options for new treatments.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!